BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35847866)

  • 1. Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.
    Di Giorgio C; Marchianò S; Marino E; Biagioli M; Roselli R; Bordoni M; Bellini R; Urbani G; Zampella A; Distrutti E; Donini A; Graziosi L; Fiorucci S
    Front Oncol; 2022; 12():939969. PubMed ID: 35847866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
    Di Giorgio C; Bellini R; Lupia A; Massa C; Urbani G; Bordoni M; Marchianò S; Rosselli R; De Gregorio R; Rapacciuolo P; Sepe V; Morretta E; Monti MC; Moraca F; Cari L; Ullah KRS; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
    Cell Oncol (Dordr); 2024 Apr; 47(2):695-710. PubMed ID: 37945798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.
    Bian SB; Yang Y; Liang WQ; Zhang KC; Chen L; Zhang ZT
    Ann N Y Acad Sci; 2021 Jan; 1484(1):74-89. PubMed ID: 32827446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
    Spencer N; Rodriguez Sanchez AL; Gopalam R; Subbarayalu P; Medina DM; Yang X; Ramirez P; Randolph L; Aller EJ; Santhamma B; Rao MK; Tekmal RR; Nair HB; Kost ER; Vadlamudi RK; Viswanadhapalli S
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
    Tang W; Ramasamy K; Pillai SMA; Santhamma B; Konda S; Pitta Venkata P; Blankenship L; Liu J; Liu Z; Altwegg KA; Ebrahimi B; Pratap UP; Li X; Valente PT; Kost E; Sareddy GR; Vadlamudi RK; Nair HB; Tekmal RR; Viswanadhapalli S
    Cell Death Discov; 2021 Aug; 7(1):216. PubMed ID: 34400617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.
    Ebrahimi B; Viswanadhapalli S; Pratap UP; Rahul G; Yang X; Pitta Venkata P; Drel V; Santhamma B; Konda S; Li X; Sanchez ALR; Yan H; Sareddy GR; Xu Z; Singh BB; Valente PT; Chen Y; Lai Z; Rao M; Kost ER; Curiel T; Tekmal RR; Nair HB; Vadlamudi RK
    NPJ Precis Oncol; 2024 May; 8(1):118. PubMed ID: 38789520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma.
    Di Giorgio C; Lupia A; Marchianò S; Bordoni M; Bellini R; Massa C; Urbani G; Roselli R; Moraca F; Sepe V; Catalanotti B; Morretta E; Monti MC; Biagioli M; Distrutti E; Zampella A; Fiorucci S
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
    Viswanadhapalli S; Luo Y; Sareddy GR; Santhamma B; Zhou M; Li M; Ma S; Sonavane R; Pratap UP; Altwegg KA; Li X; Chang A; Chávez-Riveros A; Dileep KV; Zhang KYJ; Pan X; Murali R; Bajda M; Raj GV; Brenner AJ; Manthati V; Rao MK; Tekmal RR; Nair HB; Nickisch KJ; Vadlamudi RK
    Mol Cancer Ther; 2019 Aug; 18(8):1341-1354. PubMed ID: 31142661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma.
    Di Giorgio C; Bellini R; Lupia A; Massa C; Bordoni M; Marchianò S; Rosselli R; Sepe V; Rapacciuolo P; Moraca F; Morretta E; Ricci P; Urbani G; Monti MC; Biagioli M; Distrutti E; Catalanotti B; Zampella A; Fiorucci S
    Front Oncol; 2023; 13():1140730. PubMed ID: 36998446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights.
    Halder S; Parte S; Kshirsagar P; Muniyan S; Nair HB; Batra SK; Seshacharyulu P
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188737. PubMed ID: 35680099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth.
    Blankenship L; Pratap UP; Yang X; Liu Z; Altwegg KA; Santhamma B; Ramasamy K; Konda S; Chen Y; Lai Z; Zheng S; Sareddy GR; Valente PT; Kost ER; Nair HB; Tekmal RR; Vadlamudi RK; Viswanadhapalli S
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis.
    Di Giorgio C; Morretta E; Lupia A; Bellini R; Massa C; Urbani G; Bordoni M; Marchianò S; Lachi G; Rapacciuolo P; Finamore C; Sepe V; Chiara Monti M; Moraca F; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
    Biochem Pharmacol; 2024 May; 223():116134. PubMed ID: 38494064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting LIF/LIFR signaling in cancer.
    Viswanadhapalli S; Dileep KV; Zhang KYJ; Nair HB; Vadlamudi RK
    Genes Dis; 2022 Jul; 9(4):973-980. PubMed ID: 35685476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression.
    Zhang W; Shi X; Chen R; Zhu Y; Peng S; Chang Y; Nian X; Xiao G; Fang Z; Li Y; Cao Z; Zhao L; Liu G; Sun Y; Ren S
    Mol Ther; 2020 Nov; 28(11):2473-2487. PubMed ID: 32592689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Perspectives on Leukemia Inhibitory Factor and its Receptor in Cancer.
    Christianson J; Oxford JT; Jorcyk CL
    Front Oncol; 2021; 11():693724. PubMed ID: 34395259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukaemia inhibitory factor in gastric cancer: friend or foe?
    Seeneevassen L; Martin OCB; Lehours P; Dubus P; Varon C
    Gastric Cancer; 2022 Mar; 25(2):299-305. PubMed ID: 35106710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism.
    Dhingra K; Sahin A; Emami K; Hortobagyi GN; Estrov Z
    Breast Cancer Res Treat; 1998 Mar; 48(2):165-74. PubMed ID: 9596488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0003159 upregulates LIFR expression through competitively binding to miR-221-3p/miR-222-3p to block gastric cancer development.
    Zheng L; Yan B; Jin G; Han W; Wang H; Wang Z; Ma Y; Nian Y; Meng X; Jiang Z
    J Mol Histol; 2022 Apr; 53(2):173-186. PubMed ID: 35034206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma.
    Wang HF; Lv JQ; Li HH; Wang W; Lin FQ
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5378-5384. PubMed ID: 32495872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting metastasis-initiating cancer stem cells in gastric cancer with leukaemia inhibitory factor.
    Seeneevassen L; Zaafour A; Sifré E; Genevois C; Nguyen TL; Pobiedonoscew Y; Giese A; Guignard J; Tiffon C; Rousseau B; Raymond AA; Belleannée G; Boeuf H; Gronnier C; Martin OCB; Giraud J; Lehours P; Dubus P; Varon C
    Cell Death Discov; 2024 Mar; 10(1):120. PubMed ID: 38453889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.